We collected more peripheral blood samples from responders and non-responders (18 and 12 samples, respectively) between September 2022 and June 2023, to determine the relationship between the characteristics of CD8+MAIT cells and sensitivity to anti-PD-1/PD-L1 immunotherapy in patients with NSCLC. Here, CD8A is linked to non-small cell lung carcinoma.